Description
An A2A receptor antagonist (Ki = 2.2 nM in a radioligand binding assay); inhibits haloperidol-induced catalepsy (ED50 = 0.23 mg/kg in rats); alleviates postural defects in a dose-dependent manner without inducing dyskinesias or hyperactivity in an MPTP-induced marmoset model of Parkinson’s disease; decreases bradykinesias induced by L-DOPA and improves attentional and working memory deficits in an MPTP-induced macaque model of Parkinson’s disease
Formal name: 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione
Synonyms: KW 6002
Molecular weight: 384.4
CAS: 155270-99-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease